Anixa Biosciences (NASDAQ:ANIX) Earns Buy Rating from D. Boral Capital

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They presently have a $10.00 price target on the stock. D. Boral Capital’s target price points to a potential upside of 267.65% from the stock’s previous close.

ANIX has been the topic of a number of other reports. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Monday, March 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anixa Biosciences in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Anixa Biosciences has an average rating of “Hold” and an average price target of $8.50.

Anixa Biosciences Trading Up 5.4%

Shares of NASDAQ:ANIX opened at $2.72 on Tuesday. Anixa Biosciences has a 12-month low of $2.33 and a 12-month high of $5.46. The company has a market capitalization of $91.20 million, a PE ratio of -8.24 and a beta of 0.57. The business has a 50 day moving average of $2.88 and a two-hundred day moving average of $3.52.

Anixa Biosciences (NASDAQ:ANIX) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. Equities research analysts predict that Anixa Biosciences will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling at Anixa Biosciences

In other Anixa Biosciences news, Director Arnold M. Baskies bought 10,000 shares of the firm’s stock in a transaction dated Wednesday, January 28th. The shares were purchased at an average price of $3.04 per share, for a total transaction of $30,400.00. Following the transaction, the director directly owned 135,000 shares of the company’s stock, valued at approximately $410,400. This represents a 8.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 26.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Anixa Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP acquired a new position in Anixa Biosciences during the second quarter worth $39,000. NewEdge Advisors LLC acquired a new stake in shares of Anixa Biosciences in the second quarter valued at about $33,000. Jane Street Group LLC increased its stake in shares of Anixa Biosciences by 37.2% during the second quarter. Jane Street Group LLC now owns 41,800 shares of the company’s stock worth $138,000 after purchasing an additional 11,340 shares in the last quarter. Benjamin Edwards Inc. purchased a new stake in shares of Anixa Biosciences during the second quarter worth about $37,000. Finally, World Investment Advisors acquired a new position in shares of Anixa Biosciences during the 3rd quarter worth about $48,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.